USA Rare Earth Surges 81% in H1, but Filings Show No Magnet Revenue Yet

What happened

USA Rare Earth stock surged 81% in the first half of 2026, fueled by positive developments including a sizable acquisition and policy tailwinds. However, the company's latest filings reveal that it still has not generated any revenue from neo-magnet manufacturing, with all $5.7 million in Q1 revenue coming from its Less Common Metals UK unit. The Stillwater magnet plant remains in commissioning phase, and management emphasizes it has not commenced commercial production or sales of NdFeB magnets. Moreover, the CHIPS funding package is milestone-based, and required equity raises of up to $875 million by end-2027 threaten per-share value if commercial proof lags. Until the next 10-Q shows recognized magnet revenue and actual CHIPS cash disbursement, the stock's rally prices in execution that remains unverified.

Implication

The 81% rally in H1 2026 reflects growing policy support and a sizable acquisition, but the investment thesis hinges on two binary proofs: recognized NdFeB magnet revenue and a disclosed CHIPS disbursement. As of Q1’26 filings, USAR reported zero magnet revenue, a $67 million net loss, and $1.75 billion cash—ample liquidity but no commercial magnet traction. The next catalyst is the Q2’26 10-Q (due August 2026); if it still shows no magnet revenue, the stock could re-rate sharply lower. Conversely, confirmed magnet sales and a CHIPS tranche would validate the ramp and could lift the stock toward the bull case of $32. Position sizing should reflect that dilution is embedded via required equity raises and warrant exercises, and the bear case of $12 materializes if milestone slippage or customer qualification delays persist. For now, the risk/reward is unfavorable: the stock is pricing a smooth execution that the filings have yet to substantiate.

Thesis delta

Previously, the narrative centered on policy backing and construction milestones, which drove the stock's rally. Now, the critical shift is that the next two quarters must convert commissioning into recognized magnet revenue and actual CHIPS cash—otherwise, the thesis breaks. The market is pricing success before evidence, making the stock vulnerable to disappointment if Q2'26 filings repeat the 'no revenue' language.